Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 257049

Drug Profile

GSK 257049

Alternative Names: 257049; Circumsporozoite protein hepatitis-B surface antigen fusion protein- GlaxoSmithKline; CSP-HBsAg - GlaxoSmithKline; CSP-HBsAg/SBAS2-GlaxoSmithKline; FSV-1-malaria-vaccine-GlaxoSmithKline; GSK-257146; GSK-RTS,S/AS01; GSK257049; Malaria vaccine 257049 - GlaxoSmithKline; Mosquirix; Plasmodium falciparum circumsporozoite protein/HBsAg subunit vaccine - GlaxoSmithKline; Plasmodium falciparum CSP/HBsAg - GlaxoSmithKline; Plasmodium falciparum CSP/HBsAg subunit vaccine - GlaxoSmithKline; Plasmodium falciparum malaria vaccine 257049; Profilam; QS 21 stimulon adjuvanted malaria vaccine - Agenus/GlaxoSmithKline; RTS,S; RTS,S/AS; RTS,S/AS01; RTS,S/AS01B; RTS,S/AS01E; RTS,S/AS02; RTS,S/AS02A; RTS,S/AS02D; SB-257049

Latest Information Update: 14 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Malaria Vaccine Initiative; PATH; University of Oxford
  • Class Antimalarials; Parasitic vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Falciparum malaria

Most Recent Events

  • 23 Apr 2019 Launched for Falciparum malaria (In infants, Prevention) in Malawi (IM)
  • 07 Feb 2019 GlaxoSmithKline plans a phase I/II trial for Malaria (Prevention, In volunteers) in USA in January 2019 (NCT03824236)
  • 24 Sep 2018 GlaxoSmithKline completes a phase I/II trial in Healthy volunteers in USA (IM) (NCT03162614)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top